October 24, 2016 8:14 PM ET


Company Overview of Watson Laboratories, Inc.

Company Overview

Watson Laboratories, Inc. manufactures pharmaceutical drugs. The company was incorporated in 1992 and is based in Corona, California. Watson Laboratories, Inc. operates as a subsidiary of Allergan plc.

132 Business Center Drive

Corona, CA 92880-1724

United States

Founded in 1992



Key Executives for Watson Laboratories, Inc.

Watson Laboratories, Inc. does not have any Key Executives recorded.

Watson Laboratories, Inc. Key Developments

Endo International Plc and Allergan Plc Units get Dragged to Court by US Federal Trade Commission Over Stifling Generic Competition

Endo International Plc and Allergan Plc announced that they have become the targets of a lawsuit launched by the US Federal Trade Commission (FTC), which alleges that subsidiaries of the two companies struck illegal agreements to delay the market entry of generic Opana ER and Lidoderm versions. The FTC filed its complaint on March 31, 2016, naming as guilty parties Endo Pharmaceuticals Inc, Allergan and its unit Watson Laboratories Inc, Impax Laboratories Inc, Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. The two drugs at the centre of the complaint are Endo-branded products, Opana being an extended-release opioid painkiller and Lidoderm being a topical patch for relieving post-herpetic neuralgia pain. Impax and Watson were the first companies to seek approval from the US Food and Drug Administration for generic versions of these drugs. According to the FTC, Endo paid them to postpone the launch of the generic products and these so-called pay-for-delay settlements violate US antitrust laws. The complaint alleges that Endo and Impax entered into an illegal agreement in 2010, with the latter receiving more than USD 112 million (EUR 98.2 million) to hold off the launch of its Opana ER equivalent until January 2013. The amount included USD 10 million received by Impax as part of a development and co-promotion deal struck within that period. The illegal agreement with Watson over Lidoderm was signed in May 2012 and involved Endo partners Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. as well. The FTC did not provide a specific figure for the payment received by Watson, saying only it amounted to hundreds of millions of dollars and the company pocketed a similar amount when it finally launched its generic version of the drug. This was the result of Endo's consent to refrain from selling an authorised Lidoderm generic version for seven and a half months, thus leaving Watson without any competition for a while.

Shire Wins Patent Trial against Watson Concerning LIALDA

Shire plc and its subsidiary, Shire Development LLC, announced that the United States District Court for Southern Florida has upheld its patent for LIALDA® (mesalamine) delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. The decision follows litigation by Shire against Watson Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and Watson Laboratories, Inc. in connection with their Abbreviated New Drug Application (ANDA) for a generic version of LIALDA.

Celgene Settles REVLIMID Patent Litigation with Natco Pharma Ltd., Arrow International Limited and Watson Laboratories, Inc

Celgene Corporation announced the settlement of litigation with Natco Pharma Ltd., Arrow International Limited, and Arrow’s parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for REVLIMID® (lenalidomide). As part of the settlement, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Natco from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement, as described below. In settlement of all outstanding claims in the litigation, Celgene will permit entry of generic lenalidomide before the April 2027 expiration of Celgene’s last-to-expire patent listed in the Orange Book for REVLIMID®. Celgene has agreed to provide Natco with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the United States beginning on January 31, 2026. In addition, Natco will receive a volume-limited license to sell generic lenalidomide in the United States commencing in March 2022. The volume limit is expected to be a mid-single-digit percentage of the total lenalidomide capsules dispensed in the United States during the first full year of entry. The volume limitation is expected to increase gradually each 12 months until March of 2025, and is not expected to exceed one-third of the total lenalidomide capsules dispensed in the U.S. in the final year of the volume-limited license under this agreement. Natco’s ability to market lenalidomide in the U.S. will be contingent on its obtaining approval of an Abbreviated New Drug Application.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Watson Laboratories, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.